Member Info for EmeraldCarrots

AngleSad

"Just. Stop. It’s over EC.".

====================

No, it's not. You give up too easily. Dual analysis is the key, and only Angle's lab offers it anywhere in the World (only as of the last 3 months or so). OK it's only for lung cancer at the moment but it's a big World. And it uses an Illumina assay panel. Some lung cancer drugs target certain biomarkers. If you want to find out if your lung cancer patient has these biomarkers, where do you send your blood sample for analysis? To Angle Plc because their dual analysis has twice the chance of finding the patients cancer has suitable biomarkers. Lung cancer is just the start. Remember this is WORLDWIDE.

https://webcast.openbriefing.com/angle-sept25/player/?player_id=57374

The webcast is really good. Unfortunately one big shareholder has run out of patience. I think we all have. Having said that is does look extremely promising none the less. The Myriad collaboration sounds asif it has already caused other similar Companies to speak to Angle. The Illumina lung cancer dual analysis is already offered by Angle. I suspect this will snowball. I mean, if you are looking to find biomarkers Angle's method gives you about double the chance. I am sticking with Angle as I believe they are on the verge of massive success.

https://webcast.openbriefing.com/angle-sept25/player/?player_id=57374

Submitted? No excuses. Is Gino working to bring the application dates forward as much as possible?

2. Are the Directors going to take a pay cut?

3. How does the Company spend £400,000 a month? What on?

Now the CEO has gone. If agl have been talking to half the Plc's he claimed the new management can re-visit those deals that fell through and see what can be done. A sub 10p share price is mad enough, but 3.3p! You are having a laugh. One cancer drug trial or news the dual analysis is picking up and the sp here will zoom past 10p.

Deals for so long that I eventually I convinced myself he must have a reason NOT to do deals. I kid you not! I suspected he might be mentally ill or something.

All IMHO.

No share holder with knowledge of AGL thinks the sp should be lower than 10p IMHO.It's crazy.

Share options RNS dated 21st March 2025. Minimum 18p a share I make it.

https://www.lse.co.uk/rns/AGL/issue-of-ltip-options-and-share-options-vwtxiprl74ipwwj.html

If a bid turns up the market will re-value AGL within minutes and IMHO it would be more than 15p a share. More like 20 plus like the directors share options (think they were 25p? ), and those were RNS's only months ago.

Surely a sensible bid will come in. Myriad Genetics, Illumina, Roche............. 20p plus or I'm nit interested.

Mad.

But I won't accept that.

My gut feeling in Mr Newland was asking too much when potential deals were on the table. Maybe he shoukd have done it the other way round, starting with cheaper deals to get the ball rollong. That is what I suspect anyway. Sp has recovered some now.

K3VMC.

"With AN gone, they may want to try that, but with three shareholders holding 70m+ shares, probably 30-50p average, I would hope they have to pay a decent price for the business."

====================

I'd accept 22p ish I think. I think they would too!

Maybe Brett Swansiger should resign seeing as the sales side has been a complete disaster.

All IMHO.

If they want to add CTC DNA analysis to their menu why not buy Angle?

Of taking Angle private (they woulld need 75%) so you can forget that. Newland will be back though I suspect. He will be a buyer of shares asap I am sure.

Al IMHO.

What's the betting they buy in big time now? Mr Newland may not be a good deal maker but he is not daft. I can see him and Griffiths getting in big time here. Dual analysis, Immatics phase 3, Her2, etc.............................

I don't think Mr Newland put it top priority. His priority was HER2, important yes, but dual analysis cannnot be undermined by CtDna. Angle are streets ahead with dual analysis. Their Parsortix machine means they are going to stay that way until a better machine comes along. Then that machine will have a few years of hurdles to clear too, like Parsortix did.

All IMHO.

ANGLE plc has partnered with Illumina to offer an advanced liquid biopsy solution that combines the analysis of circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) DNA from a single blood sample. This dual analysis, known as "dual analysis," utilizes ANGLE's Parsortix system to isolate intact CTCs and Illumina's sequencing platforms and assays to analyze both CTC-DNA and ctDNA. The collaboration has shown significant results in lung cancer research, revealing that CTC-DNA provides crucial biomarkers not found in ctDNA alone, which can improve cancer treatment precision and drug development.

Key aspects of the ANGLE plc and Illumina dual analysis collaboration:

End-to-end solution:

The partnership provides a complete workflow, starting from the Parsortix system for sample preparation to Illumina's NextSeq 2000 platform and specialist assays for DNA analysis.

Dual analysis:

The method involves analyzing two distinct types of tumor-derived material from a single blood sample: ctDNA (fragmented DNA in plasma) and CTC-DNA (DNA from intact circulating tumor cells).

Clinical benefits:

The dual analysis approach offers a more comprehensive view of a patient's tumor biology. It identifies clinically relevant mutations in CTC-DNA that are absent in ctDNA, which is not possible with ctDNA-only analysis.

Application in lung cancer:

A key study on 27 lung cancer patients using an Illumina 79-gene lung cancer panel showed that 100% of treatment-naïve patients and 90% of treated patients had actionable DNA variants only in CTC-DNA.

Enhanced drug development:

This approach provides biopharmaceutical partners with a valuable tool for identifying resistance mechanisms, selecting patients for clinical trials, and potentially reducing the need for invasive tissue biopsies.

Collaboration highlights:

ANGLE has presented data on this dual analysis workflow at an EACR-Illumina webinar, marking the beginning of a co-marketing initiative with Illumina.

They offer works, and is available as of about the last 3 or 4 months.

I believe Angle's biggest issue is their sales side. Maybe Mr Newland was part of the problem by I assume pushing for better deals than the clients were willing to agree. Maybe now he has gone more deals will be done.

Biomarkers need to be found in/on the cancer cells so you are eligible for the specific treatment. Angle's "dual analysis" finds about DOUBLE the amount of biomarkers standard CtDna analysis does!! DOUBE FFS! Angle Plc should be innundated with requests to analyse blood samples from lung cancer patients!!!!

What is wrong with the sales team there? Maybe it's because this service has only been available about the last 3 months?? Their sales team need to get on it!!!

===================

So if you are going to have a blood CtDna analysis done to try to find a specific biomarker for your lung cancer YOU NEED TO HAVE THE ONE ANGLE Plc offer to double your chances!!!! It could not be more obvious. The sales team at Angle Plc should be shouting this out loud!

All IMHO.